Clinical cases have indicated an increase in peripheral blood flow after continuous epidural spinal cord stimulation (SCS) and that reduced muscle sympathetic nerve activity (MSNA) might be a potential mechanism. However, no studies in humans have directly examined the effects of acute SCS (<60 min) on vascular conductance and MSNA. In study 1, we tested the hypothesis that acute SCS (<60 min) of the thoracic spine would lead to increased common femoral vascular conductance, but not brachial vascular conductance, in 11 patients who previously underwent surgical SCS implantation for management of neuropathic pain. Throughout 60 min of SCS, common femoral artery conductance was elevated and significantly different from brachial artery conductance [in millilitres per minute: 15 min, change (Δ) 26 ± 37 versus Δ−2 ± 19%; 30 min, Δ28 ± 45 versus Δ0 ± 26%; 45 min, Δ48 ± 43 versus Δ2 ± 21%; 60 min, Δ36 ± 61 versus Δ1 ± 24%; and 15 min post-SCS, Δ51 ± 64 versus Δ6 ± 33%; P = 0.013].
INTRODUCTION
Electrical stimulation of neurons within the dorsal columns of the spinal cord [spinal cord stimulation (SCS)] is a neuromodulation therapy for increasing blood flow to the extremities. In patients with peripheral artery disease, continuous SCS leads to an increase in circulation and a subsequent reduction in ischaemic pain (Linderoth & Foreman, 1999) and promotes healing of ischaemic ulcers, probably through improved microcirculation (Cook, Oygar, Baggenstos, Pacheco, & Kleriga, 1976; Jacobs et al., 1988) . Spinal cord stimulation acts on multiple pathways in the CNS and is therefore used to treat a variety of other conditions, such as neuropathic pain (e.g. c 2018 The Authors. Experimental Physiology c 2018 The Physiological Society chronic back and/or lower extremity pain; Epstein & Palmieri, 2012; Manchikanti et al., 2013) , angina pectoris and ventricular arrhythmias (Mannheimer, Augustinsson, Carlsson, Manhem, & Wilhelmsson, 1988; Odenstedt et al., 2011) . However, despite the long history of SCS, which spans nearly six decades, studies have yet to elucidate fully the specific mechanisms by which SCS provides benefit in humans.
What we know about the effects of SCS on peripheral blood flow stems largely from outcomes of months or years of patient treatment.It is unclear whether acute SCS treatment has immediate effects on lower limb blood flow. Evidence supports an increase in cerebral blood flow after acute (<60 min) cervical SCS (Hautvast et al., 1997; Meglio et al., 1991 • What is the main finding and its importance?
Acute spinal cord stimulation led to a rapid rise in femoral vascular conductance, and peroneal muscle sympathetic nerve activity demonstrated a delayed reduction that was not associated with the initial increase in femoral vascular conductance. These findings suggest that neural mechanisms in addition to attenuated muscle sympathetic nerve activity might be involved in the initial increase in femoral vascular conductance during acute spinal cord stimulation.
measuring arterial pulse pressure at the toe reported that acute (<60 min) SCS increased arterial dilatation (Dooley & Kasprak, 1976) .
Some evidence suggests that continuous SCS (Jacobs et al., 1988) , but not acute SCS (Kemler, Barendse, van Kleef, & Egbrink, 2000) , increases cutaneous blood flow, although studies were performed in patients with a history of sympathectomy and/or vascular surgery. To our knowledge, no studies in humans have directly examined the acute effects of SCS (<60 min) on leg vascular conductance.
Reduction in muscle sympathetic nerve activity (MSNA) has been considered a potential mechanism of action by which SCS improves circulation (Linderoth & Foreman, 1999) . The theory that SCS reduces MSNA originated from clinical observations of pain relief (Augustinsson, Carlsson, Holm, & Jivegard, 1985) and normalization in measures of peripheral blood flow after SCS in patients with peripheral vascular disease (Broseta et al., 1986; Horsch, Schulte, & Hess, 2004) . The increase in limb blood flow after SCS appears to mimic the effects of sympathetic block or sympathectomy (Augustinsson et al., 1985; Linderoth, Gunasekera, & Meyerson, 1991) . However,
animal models of SCS have demonstrated that extremity blood flow can increase independent of sympathetic inhibition depending on the stimulation parameters used (Croom, Foreman, Chandler, & Barron, 1997) . To date, no studies have directly examined MSNA responses to SCS in humans. Moreover, studies of circulatory improvement with SCS often include patients with sympathectomy, which makes interpretation of the effects of SCS on sympathetic activity difficult. Thus, whether acute SCS-mediated increases in blood flow in the lower limbs can be associated with reduced MSNA remains unclear.
In the present study, we tested the hypothesis that acute SCS (60 min) significantly increases leg vascular conductance. Patients studied herein previously received surgical SCS implantation to treat neuropathic conditions (e.g. chronic back pain). Therefore, SCS lead placement and configurations were optimized to induce paraesthesiae and provide neuropathic pain relief and were perhaps not ideal for influencing leg blood flow. Nonetheless, we performed these studies to provide proof of concept that acute SCS increases leg blood flow in addition to the neuropathic pain relief that these patients typically experience with SCS. Given that SCS implants were at the level of the thoracic spine, we hypothesized that acute SCS would increase femoral vascular conductance, but not brachial vascular conductance.
One patient with cervical SCS was also studied to observe whether femoral vascular conductance can be increased with acute cervical SCS. In addition, to examine whether increased femoral vascular conductance after acute SCS can be associated with decreased MSNA, we performed a second study in a subset of the SCS patients, in which MSNA was measured in response to acute SCS.
METHODS

Ethical approval
Studies conformed to the standards set by the latest revision of 
Subjects
Twelve patients (54 ± 12 years old; five men and seven women) who had undergone SCS implantation (2.5 ± 1.3 years previously) to treat neuropathic pain originating in the lower back and/or limbs were recruited through the Department of Neurosurgery at the University of Iowa Hospitals and Clinics. Subject characteristics are presented in Table 1 . Eleven of the 12 patients had thoracic SCS implants, and one patient (patient 11) had cervical SCS implants. With each patient's condition in mind, patients were studied and evaluated in protocol 1 (vascular conductance responses to 60 min of SCS) and, based on the level of ease in which protocol 1 was performed, patients returned to participate in protocol 2 (MSNA responses to 60 min of SCS).
Patients were excluded from this study if previously diagnosed or suffered from peripheral vascular disease, heart disease, renal failure, type 1 diabetes, cancer, autonomic dysfunction, had a history of sympathectomy or any form of heart surgery. Six patients had a history of hypertension, five of whom were currently taking antihypertensive medication (Table 1) .
Epidural dorsal column stimulation
The spinal cord stimulator consists of a lead wire with up to 16 electrodes implanted posterior to the dorsal column of the spinal cord, and a pulse generator with a rechargeable battery to deliver electrical current (Epstein & Palmieri, 2012; Holland et al., 2016) . The SCS device is controlled via a hand-held wireless remote control, which has the capability to turn the device on and off and adjust programs that determine the level of stimulation. Individual patient electrode implant 
Muscle sympathetic nerve activity
Multiunit MSNA was recorded using standard microneurographic techniques as previously described Holwerda, Vianna et al., 2016; Vallbo, Hagbarth, Torebjörk, & Wallin, 1979) . Briefly, a tungsten microelectrode was placed into the peroneal nerve near the left fibular head. Signals were amplified, filtered (bandwidth 0.7-2.0 kHz), rectified and integrated (0.1 s time constant)
to obtain mean voltage neurograms (Nerve Traffic Analyzer 662c-3; University of Iowa Bioengineering, Iowa City, IA, USA). The MSNA data were acquired at a frequency of 1000 Hz using a Powerlab data acquisition system (ADInstruments, Colorado Springs, CO, USA) and analysed using LabChart version 8.1.5 (ADInstruments).
Muscle sympathetic nerve activity was identified by the presence of spontaneous bursts with characteristic pulse synchronicity and by its responsiveness to end-expiratory breath holds, but not to arousal or skin stimulation.
Experimental protocols 2.5.1 Study 1: Femoral and brachial vascular conductance responses to acute SCS
SCS study patients (n = 12) arrived at the University of Iowa Clinical
Research Unit after an overnight fast. Study patients were instructed to deactivate their SCS unit and abstain from vasoactive medications for 48 h before the study visit and to abstain from caffeine on the morning of the study. Previous studies of acute SCS used a 24 h washout of SCS (Kemler et al., 2000) ; however, in the present study, deactivation of SCS was extended to 48 h before the study visit to maximize washout of electrical stimulation, but without overburdening patients by limiting their pain management strategy. Study visits were initiated between 07.00 and 09.00 h and were performed in a quiet, dimly lit, temperature-controlled room (21-22 • C). After a 15 min rest period, patients were instrumented for heart rate (HR, determined from lead II of the three-lead ECG), blood pressure (BP; arm cuff) and femoral and brachial artery blood flow. After baseline measurements of femoral and brachial artery blood flow, the SCS unit was activated via remote control at the individual patient's clinically prescribed level of stimulation (see Table 1 ), and femoral and brachial artery blood flow was measured every 15 min during SCS (60 min) and 15 min post-SCS. The SCS unit can be sensed by patients when functioning (typically described as paraesthesiae or a sensation of vibration); therefore, a sham condition in the study protocol was precluded. The visual analog score of neuropathic pain on a scale of 0-10 was reported by the patient at each time point.
2.5.2
Study 2: Influence of acute SCS on muscle sympathetic nerve activity Lead location  T6-T8  Left: T8-T9  Right: T9-T10   T8-T9  T6-T8  T7-T9  T9- 
Data analysis
Patient 1 (a-d) Baseline (a) (e) (b) (f) (j) (c) (g) (k) (d) (h) (l)(i)
Cardiovascular responses to acute SCS
No changes in HR were observed throughout SCS (in beats per minute:
BL, 60 ± 6; 15 min, 59 ± 7; 30 min, 60 ± 8; 45 min, 60 ± 8; 60 min, 61 ± 8; 15 min post, 60 ± 6; P = 0.778). Although there were no significant changes in systolic BP (P = 0.086) or diastolic BP (P = 0.133) during SCS, there was a small but significant increase in mean BP (in millimetres of mercury: BL, 87 ± 10; 15 min, 90 ± 11; 30 min, 92 ± 11; 45 min, 90 ± 12; 60 min, 91 ± 12; 15 min post, 87 ± 13; P = 0.012).
The increase in mean BP was consistent among patients. As expected, self-reported neuropathic pain was reduced after SCS and remained reduced throughout SCS (scale 0-10: BL, 3.5 ± 3.3; 15 min, 1.7 ± 2.2; 30 min, 1.6 ± 1.9; 45 min, 1.6 ± 2.1; 60 min, 1.6 ± 2.1; 15 min post, 2.2 ± 3.0; P = 0.003).
Study 2 3.2.1 Influence of acute SCS on muscle sympathetic nerve activity
MSNA during SCS gradually declined and became significantly reduced at 45 and 60 min of SCS compared with baseline and 15 min (P = 0.015; 
Cardiovascular responses to acute SCS
Similar to study 1, no change in HR was observed during SCS (in beats per minute: BL, 63 ± 9; 15 min, 64 ± 10; 30 min, 64 ± 10; 45 min, 64 ± 9; 60 min, 65 ± 9; 15 min post, 67 ± 12; P = 0.197). Also, no significant changes in systolic BP (P = 0.773) and diastolic BP (P = 0.598) were observed. Mean BP during SCS was not significantly different compared with baseline (in millimetres of mercury: BL, 90 ± 7; 15 min, 91 ± 11; 30 min, 92 ± 10; 45 min, 91 ± 11; 60 min, 93 ± 11; 15 min post, 86 ± 14; P = 0.197), although the pattern tended to be similar to that of study 1. Neuropathic pain appeared reduced within the first 15 min and remain unchanged thereafter, although not reaching statistical significance (scale 0-10: BL, 2.2 ± 1.3; 15 min, 0.8 ± 0.8; 30 min, 0.6 ± 0.9; 45 min, 0.8 ± 1.1; 60 min, 0.6 ± 0.9; 15 min post, 1.8 ± 1.9; P = 0.098).
DISCUSSION
There are two major new findings of the present study. (Salminen, Rimpilä, & Polo, 2014) , with SCS leads spanning the T10-T11 vertebral bodies (Holland et al., 2016) . SCS mediated vasodilatation is hypothesized to occur via reduction of efferent sympathetic nerve activity in the periphery, whereas the mechanism of action by which SCS effectively treats neuropathic conditions such as chronic back pain involves the blockade of afferent nociceptive information ascending the spinal cord (Epstein & Palmieri, 2012; Manchikanti et al., 2013) .
Experimental animal studies have provided evidence that SCS leads to vasodilatation via a reduction in sympathetic activity (Linderoth et al., 1991; Linderoth, Herregodts, & Meyerson, 1994) .
It is proposed that SCS activation of afferent sensory fibres in the dorsal columns stimulates GABAergic interneurons, which reduce activity of sympathetic preganglionic neurons and peripheral release of noradrenaline (Foreman & Linderoth, 2012) . The present study is the first to examine efferent sympathetic activity to muscle of the lower limbs in patients with SCS directly. The results support and extend findings from experimental animal studies that demonstrate increased peripheral blood flow via SCS modulation of sympathetic activity. Our findings are also consistent with human studies that have examined the influence of SCS on circulating noradrenaline during atrial pacing-induced myocardial stress (Norrsell et al., 1997) .
Results of these studies demonstrated a blunted increase in total body noradrenaline spillover during application of SCS, indicating that SCS decreased efferent sympathetic activity. However, the aforementioned study also demonstrated no change in cardiac sympathetic activity during SCS, which is consistent with a more recent study by Naar et al. (2017) . These findings support a preferential reduction in sympathetic nerve activity to the periphery during SCS. Tanaka, Barron, Chandler, Linderoth, & Foreman, 2003) . However, a stimulation frequency higher than typically used in the clinic is likely to be required to activate small myelinated sensory fibres and cause release of CGRP (Gao et al., 2010) . Consistent with this, studies of acute SCS (<60 min) in patients with complex regional pain syndrome failed to demonstrate an increase in skin microcirculation (Kemler et al., 2000) . Thus, it is unlikely that activation of small myelinated sensory fibres played a major role in SCS-mediated increases in femoral vascular conductance. SCS mediated vasodilatation in other vascular beds, such as in the splanchnic circulation, should also be considered. Reduction in abdominal pain after SCS in a patient with mesenteric ischaemia has previously been reported, suggesting SCS-mediated vasodilatation in the splanchnic circulation (Ceballos, Cabezudo, Bovaira, Fenollosa, & Moro, 2000) . Despite increased vascular conductance, a small but significant increase in mean BP during SCS was observed, and BP appeared to return towards baseline after SCS. The reason(s) behind this increase in BP are unclear. In response to increased femoral vascular conductance, and presumably an initial reduction in BP, baroreflex-mediated increases in sympathetic activity would have been expected, although assessment of increased sympathetic activity is limited because MSNA in the leg was at least partly blocked by SCS.
However, no changes in HR were observed during SCS, suggesting that the increase in BP was probably not mediated by the baroreflex.
An important consideration is the influence of SCS on neural control of the bladder. Bladder activation can occur with SCS by activation of preganglionic parasympathetic fibres to the detrusor muscle (Rijkhoff, Wijkstra, van Kerrebroeck, & Debruyne, 1997) , which has previously been a point of focus in paraplegic animal and human studies (Friedman, Nashold, & Senechal, 1972; Grimes & Nashold, 1974) .
Although SCS lead placement was not ideal for bladder activation, the need to empty the bladder during SCS was frequently reported by patients in the present study. Thus, urinary retention and related discomfort, which was not covered by neuropathic pain self-reports collected during the study, is considered a potential factor explaining the small increase in BP during SCS.
Given that the patients studied here were receiving SCS for neuropathic pain management, whether reduced MSNA and increased femoral vascular conductance during SCS can be explained by a reduction in neuropathic pain warrants discussion. Pain relief associated with deep brain stimulation in patients with neuropathic pain can influence the sympathetic firing pattern (Sverrisdóttir et al., 2014) . In healthy individuals, MSNA responses to tonic muscle pain differ; some individuals demonstrate a sustained increase in MSNA, whereas others demonstrate a reduction (Fazalbhoy, Birznieks, & Macefield, 2012) . In the present study, the reduction in self-reported neuropathic pain immediately followed initiation of SCS (15 min), whereas MSNA followed a pattern of a progressive decline, suggesting that neuropathic pain and changes in MSNA were dissociated. Although an increase in femoral vascular conductance was observed with thoracic SCS, no major change in femoral vascular conductance was observed in patient 11, who had cervical SCS.
Previous studies have demonstrated increases in cerebral blood flow after acute cervical SCS (Hautvast et al., 1997; Hosobuchi, 1985; Meglio et al., 1991) . Cervical SCS is also used to manage unstable angina (González-Darder, Canela, & González-Martinez, 1991; Hautvast, DeJongste, Staal, van Gilst, & Lie, 1998) , cluster headache (Wolter, Kiemen, & Kaube, 2011) and upper limb neuropathic pain, which was the case for patient 11 in the present study. To our knowledge, no studies have demonstrated increased limb blood flow (arm or leg) in response to cervical SCS. Despite no major changes in limb blood flow in the present study, patient 11 did demonstrate a considerable reduction in peroneal MSNA after SCS during study visit 2. These data highlight our overall observation that increased femoral vascular conductance after SCS was not directly proportional to reduced peroneal MSNA as hypothesized, and that additional neural mechanisms are likely to be involved.
Several limiting factors should be acknowledged in the present study. First, although our study findings demonstrate proof of concept that SCS increases femoral conductance and reduces MSNA in humans, the study design lacked a placebo condition to compare with SCS. Paraesthesiae or the sensation of vibration that occurs with typical SCS parameters prevented a true placebo condition. However, future investigations might also include time controls with no SCS.
Second, the number of observations was limited, particularly for measures of MSNA (blood flow, n = 12; MSNA, n = 5). Although selfreported neuropathic pain during the study was only moderate, the ability to rest comfortably and still for stable 60 min peroneal MSNA recordings was limited for this patient population.
In summary, we demonstrate, for the first time in humans, that acute SCS significantly increases femoral vascular conductance. In addition,
peroneal MSNA was significantly attenuated in response to acute SCS. However, in contrast to the rapid increase in femoral vascular conductance, peroneal MSNA in response to acute SCS demonstrated a progressive reduction and did not appear to be associated directly with the change in femoral vascular conductance. Neural mechanisms in addition to attenuated MSNA might be involved in the initial SCSmediated increases in femoral vascular conductance.
